- Home
- MGX vs IAE Comparison
MGX vs IAE Comparison
Compare MGX & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGX
- IAE
- Stock Information
- Founded
- MGX 2018
- IAE 2007
- Country
- MGX United States
- IAE United States
- Employees
- MGX N/A
- IAE N/A
- Industry
- MGX
- IAE Trusts Except Educational Religious and Charitable
- Sector
- MGX
- IAE Finance
- Exchange
- MGX NYSE
- IAE Nasdaq
- Market Cap
- MGX 62.1M
- IAE 65.2M
- IPO Year
- MGX 2024
- IAE N/A
- Fundamental
- Price
- MGX $1.45
- IAE $6.83
- Analyst Decision
- MGX Strong Buy
- IAE
- Analyst Count
- MGX 4
- IAE 0
- Target Price
- MGX $13.00
- IAE N/A
- AVG Volume (30 Days)
- MGX 417.1K
- IAE 46.3K
- Earning Date
- MGX 08-13-2025
- IAE 01-01-0001
- Dividend Yield
- MGX N/A
- IAE 10.21%
- EPS Growth
- MGX N/A
- IAE N/A
- EPS
- MGX N/A
- IAE N/A
- Revenue
- MGX $45,263,000.00
- IAE N/A
- Revenue This Year
- MGX N/A
- IAE N/A
- Revenue Next Year
- MGX $11.75
- IAE N/A
- P/E Ratio
- MGX N/A
- IAE N/A
- Revenue Growth
- MGX N/A
- IAE N/A
- 52 Week Low
- MGX $1.23
- IAE $5.31
- 52 Week High
- MGX $5.50
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- MGX 40.18
- IAE 65.51
- Support Level
- MGX $1.41
- IAE $6.77
- Resistance Level
- MGX $1.59
- IAE $6.91
- Average True Range (ATR)
- MGX 0.13
- IAE 0.06
- MACD
- MGX -0.02
- IAE -0.02
- Stochastic Oscillator
- MGX 11.32
- IAE 59.95
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.